5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Investing.com - Goldman Sachs initiated coverage on Carlsmed Inc (NASDAQ:CARL) with a Buy rating and a $19.00 price target, representing approximately 40% upside potential from current levels. According to InvestingPro data, the stock’s RSI suggests overbought conditions, with shares trading near $13.58, about 11% below their 52-week high of $15.20.
The investment bank cited Carlsmed’s differentiated technology position, projected revenue growth trajectory, and asset-light business model that accelerates its path to profitability as key factors supporting the positive outlook.
Carlsmed is an emerging growth stage medical technology company that specializes in customized spinal implants and AI-enabled surgical planning software for spinal fusion surgeries.
The company’s core platform, Aprevo, utilizes CT imaging to custom design and 3D print interbody implants tailored to each patient’s unique pathology, including AI-enabled planning software and single-use instruments for procedures.
Goldman Sachs noted that Aprevo’s goal is to improve surgical outcomes, increase patient satisfaction, and ultimately reduce healthcare costs by decreasing the need for revision procedures.
In other recent news, Carlsmed, Inc. has begun trading on the Nasdaq Global Select Market with an initial public offering (IPO) price set at $15 per share. This pricing aligns with the company’s earlier announcement that shares would be priced between $14 and $16. Carlsmed is offering a total of 6,700,000 shares of common stock, with the potential for underwriters to purchase an additional 1,005,000 shares. The company anticipates gross proceeds of approximately $100.5 million from the offering, excluding underwriting discounts, commissions, and other expenses. The offering is expected to close soon, pending customary closing conditions. These developments mark Carlsmed’s entry into the public market, where it will trade under the ticker symbol "CARL."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.